Genmab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 10, 2025

Genmab (CPH:GMAB) First Quarter 2025 Results

Key Financial Results

Revenue: kr.715.0m (up 19% from 1Q 2024).
Net income: kr.195.0m (up 1.6% from 1Q 2024).
Profit margin: 27% (down from 32% in 1Q 2024). The decrease in margin was driven by higher expenses.
EPS: kr.3.06 (up from kr.2.96 in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — CPSE:GMAB Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genmab EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe.

Performance of the market in Denmark.

The company's shares are down 7.2% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Genmab's balance sheet.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.